Dr. Hui Xiong | Pharmaceutics | Best Researcher Award
Associate Professor | China Pharmaceutical University | China
Dr. Hui Xiong is an Associate Professor in the Department of Pharmaceutics at China Pharmaceutical University, where she leads pioneering research in advanced drug delivery systems and nanomedicine engineering. She earned her Ph.D. in Pharmaceutics and has since focused her career on the rational design of multifunctional nanocarriers to improve the bioavailability, targeting precision, and therapeutic index of anticancer drugs. Her work integrates pharmaceutics, tumor biology, and materials science to develop innovative delivery platforms for combination therapy, pH-activated antiangiogenic chemotherapy, tumor microenvironment modulation, and ferroptosis-inducing therapeutic strategies, with a strong emphasis on breast and pancreatic cancer treatment. Dr. Xiong has published over 30 SCI papers as first or corresponding author in leading journals such as ACS Nano, Nano Letters, Journal of Controlled Release, Small, and Advanced Healthcare Materials, accumulating a total impact factor exceeding 188 and an H-index of 16. Her contributions include groundbreaking studies on vascular normalization, metabolic symbiosis-blocking nanocombinations, bioengineered nanospores for macrophage modulation, and redox-regulated nanodrugs, several of which have been featured on journal covers. She has been the principal investigator for multiple National Natural Science Foundation of China projects and holds four national invention patents, advancing translational pharmaceutics for clinical oncology. Recognized for her contributions to cancer nanomedicine, she also serves as a peer reviewer for several high-impact journals, further shaping the direction of pharmaceutics and targeted drug delivery research.
Profile : ORCID
Publications
1. He, Z., Wang, R., Qi, Y., Liu, Y., Xiong, H.*, & Yao, J. (2024). Nanocoated bacteria with H₂S generation-triggered self-amplified photothermal and photodynamic effect for breast cancer therapy. Journal of Controlled Release.
2. Qiao, J., Liu, S., Huang, Y., Zhu, X., Xue, C., Wang, Y., Xiong, H.*, & Yao, J. (2024). Glycolysis–noncanonical glutamine dual-metabolism regulation nanodrug enhanced the phototherapy effect for pancreatic ductal adenocarcinoma treatment. Journal of Colloid and Interface Science.
3. Yao, L., Zhu, X., Shan, Y., Zhang, L., Yao, J., & Xiong, H.* (2024). Recent progress in anti-tumor nanodrugs based on tumor microenvironment redox regulation. Small.
4. Shang, Y., Lu, H., Liao, L., Li, S., Xiong, H.*, & Yao, J. (2023). Bioengineered nanospores selectively blocking LC3-associated phagocytosis in tumor-associated macrophages potentiate antitumor immunity. ACS Nano.
5. Xiong, H., Liu, X., Xie, Z., Zhu, L., Lu, H., Wang, C., & Yao, J. (2022). Metabolic symbiosis-blocking nanocombination for tumor vascular normalization treatment. Advanced Healthcare Materials.